Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Schedule Research Team

Updated Oct 8, 2026

Popular peptides right now

Ranked by activity on Peptide Schedule and Google search demand over the last 30 days. 41 of 150 peptides clear the bar. Popular is not the same as safe: every card shows the safety grade, the FDA status and how published research and community reports line up. This ranking is more than two weeks old.

  1. 1HGH 191AA

    HGH 191AA is recombinant somatropin, the same 191-amino-acid growth hormone your pituitary makes. FDA-approved for growth hormone deficiency, it's used off-label for fat loss, recovery, and anti-aging at doses well above clinical guidelines. Quality varies wildly by source and manufacturer.

    Growth HormoneFDA approvedGrade A
    ResearchStrongCommunityStrongCalculator
  2. 2Retatrutide

    Retatrutide is a triple-agonist peptide (GLP-1, GIP, glucagon) that cut body weight 25.0% at 80 weeks in the peer-reviewed TRIUMPH-1 trial. Not yet FDA approved. Liver fat fell more than 80% on 8 and 12 mg in a Phase 2 MASLD substudy.

    Weight LossInvestigationalGrade BRising
    ResearchStrongCommunityModerateCalculator
  3. CJC-1295 plus Ipamorelin is the most popular pre-mixed GH secretagogue stack, valued for clean growth hormone release without cortisol or appetite spikes. Sleep improvements appear within two weeks. Body composition shifts follow by month two. No RCT exists for the combo, but individual-component data and thousands of community reports align closely.

    Growth HormoneResearch onlyGrade BRising
    ResearchWeakCommunityStrongCalculator
  4. Kisspeptin-10 triggers LH and testosterone release by activating the hypothalamic KISS1R receptor upstream of GnRH. Researchers study it in reproductive physiology; post-TRT use comes from the community. Constant exposure can desensitize the receptor. Community dosing runs 100 to 200 mcg subcutaneous daily or 5 days a week.

    Sexual HealthResearch onlyGrade B
    ResearchModerateCommunityWeakCalculator
  5. HGH (Somatropin) is FDA-approved recombinant growth hormone, with observational safety data on 15,809 GH-deficient adults (KIMS). Rudman's foundational study showed 8.8% lean mass gain and 14.4% fat loss in six months. Pharma-grade pricing remains steep, but anti-aging protocols at 1 to 2 IU daily are the community standard for sleep, skin, and body composition.

    Growth HormoneFDA approvedGrade A
    ResearchStrongCommunityStrongCalculator
  6. 6AHK-Cu

    AHK-Cu is a copper tripeptide with one published study showing hair follicle stimulation in vitro. Community use is mostly topical at 0.5 to 1% concentration. Injectable protocols exist but lack any direct scientific backing beyond structural similarity to GHK-Cu, which carries a far broader published evidence base.

    Anti-AgingResearch onlyGrade C
    ResearchWeakCommunityWeakCalculator
  7. The Wolverine Stack (BPC-157 + TB-500) combines two healing peptides in one pre-mixed vial. One retrospective report gave 4 of 16 knee pain patients the combination; 3 of 4 reported significant relief. Thousands of community reports describe faster healing, though the one controlled rat study (PMID 42542926) found no added benefit over either peptide alone. No dedicated clinical trial exists yet.

    Healing & RecoveryNot FDA approvedGrade C
    ResearchWeakCommunityStrongCalculator
  8. Bromantane upregulates dopamine synthesis enzymes for calm, crash-free motivation. Approved in Russia for neurasthenia; an uncontrolled 728-patient study reported 90.8% CGI-I responders. Not FDA-approved; prohibited in competition by WADA. Oral dosing at 50 to 100 mg daily for 4 weeks, then 2 to 4 weeks off (community reports).

    CognitiveNot FDA approvedGrade CRising
    ResearchModerateCommunityModerate
  9. 9BPC-157

    BPC-157 is the most popular healing peptide in the world, backed by 180+ PubMed papers and years of consistent community reports. Community evidence for tendon and gut repair is hard to dismiss, though FDA counted only about 80 people across five small human studies.

    Healing & RecoveryNot FDA approvedGrade C
    ResearchModerateCommunityStrongCalculator
  10. 10Dermorphin

    Dermorphin is a frog-derived opioid peptide about 30-40x as potent as morphine in isolated-tissue tests. A 1985 trial in 150 surgical patients found intrathecal dermorphin outlasted morphine; no later pain trial followed. Not federally scheduled, and FDA has not approved it for humans or animals. Research reference only, not for human use.

    Healing & RecoveryNot FDA approvedGrade D

    An opioid peptide with a grade D safety rating and one human trial, from 1985. Popular is not the same as safe.

    ResearchWeakCommunityWeakCalculator
  11. 11PEG-MGF

    PEG-MGF is a PEGylated copy of MGF, a muscle repair signal, built to last longer; its 48 to 72 hour half-life is an estimate. Community users report faster recovery and reduced soreness within weeks. All published research tested native MGF, not the PEGylated form. Research peptide only.

    Growth HormoneNot FDA approvedGrade C
    ResearchNoneCommunityWeakCalculator
  12. 12ARA-290

    ARA-290 (cibinetide) activates the innate repair receptor to drive small nerve fiber regeneration without affecting red blood cell production. Phase 2b trials in sarcoidosis neuropathy showed a 23% increase in corneal nerve fiber area at the 4 mg dose. Research-only; no Phase 3 registered.

    Healing & RecoveryPhase 2Grade BRising
    ResearchModerateCommunityWeakCalculator
  13. 13MOTS-c

    MOTS-c activates the same AMPK pathway triggered by exercise, making it one of the few true exercise mimetics. Preclinical data shows fat loss and insulin sensitization in mice; community users report improved endurance and glucose control within 2 to 4 weeks.

    MetabolicNot FDA approvedGrade B
    ResearchModerateCommunityModerateCalculator
  14. 14GHK-Cu

    GHK-Cu raises or lowers the activity of at least 4,000 human genes, including ones tied to collagen, wound repair, and aging. Community reports consistently describe firmer skin by week four and faster healing. No human injectable RCTs exist yet, but topical trials and decades of in vitro data back its core mechanisms. Available as subcutaneous injection or topical serum.

    Anti-AgingNot FDA approvedGrade B
    ResearchModerateCommunityStrongCalculator
  15. 15Tirzepatide

    Tirzepatide targets both GIP and GLP-1 receptors, producing 20-22% body weight loss in important trials. FDA-approved as Zepbound (obesity) and Mounjaro (T2D). GI side effects during titration are the main limiting factor; a black box warning for thyroid tumors applies.

    Weight LossFDA approvedGrade A
    ResearchStrongCommunityStrongCalculator
  16. Cagrilintide activates amylin receptors, a pathway GLP-1 drugs miss entirely. REDEFINE 1 confirmed 11.5% weight loss as monotherapy and 20.4% combined with semaglutide at 68 weeks. CagriSema NDA is under FDA review. All standalone supply remains research-grade with no regulatory oversight.

    Weight LossPhase 3Grade B
    ResearchStrongCommunityModerateCalculator
  17. MK-677 (Ibutamoren) is an oral growth hormone secretagogue backed by a 2-year RCT in healthy elderly adults. It raises IGF-1 40 to 60 percent without suppressing your natural GH axis. Appetite stimulation and insulin resistance are the main limitations. Research compound, not FDA approved.

    Growth HormoneResearch onlyGrade C
    ResearchStrongCommunityStrong
  18. 18ACE-031

    ACE-031 traps myostatin to promote lean mass gains. Phase 1 showed 3.3% muscle increase from one injection, but vascular safety signals halted clinical development. Community protocols use doses far below trial levels. Quality verification is difficult for this recombinant fusion protein.

    Growth HormoneResearch onlyGrade C
    ResearchModerateCommunityWeakCalculator
  19. 19AOD-9604

    In obese mice, AOD-9604 raised fat breakdown without cutting food intake, unlike appetite-based weight loss drugs; its molecular target is unknown. A 12-week oral trial works out to about 2.6 kg of weight loss versus 0.8 kg on placebo. The Phase IIb trial failed its primary endpoint. Community users treat it as a mild recomposition stacking add-on, not a standalone solution.

    Weight LossPhase 2Grade B
    ResearchWeakCommunityModerateCalculator
  20. 20Dihexa

    Dihexa (PNB-0408) activates the HGF/c-Met pathway to promote synaptogenesis in animal models. No human trials exist. Two founding papers were retracted in 2025 for data fabrication. Community dosing runs 5 to 20 mg daily oral. Strictly experimental and unverified.

    CognitiveNot FDA approvedGrade C
    ResearchWeakCommunityWeakCalculator
  21. 21Semaglutide

    Semaglutide holds four FDA approvals for obesity, type 2 diabetes, and cardiovascular risk reduction. STEP 1 confirmed 14.9% mean weight loss at 68 weeks. The 7.2 mg high-dose version (March 2026) pushes that to 18.7%. GI side effects are real but manageable with slow titration.

    Weight LossFDA approvedGrade A
    ResearchStrongCommunityStrongCalculator
  22. 22Semax

    Semax triples hippocampal BDNF in rodent models and is approved for stroke recovery in Russia. Short 10 to 20 day intranasal or subcutaneous cycles produce focus and memory benefits that persist weeks after stopping. No RCTs in healthy adults exist.

    CognitiveNot FDA approvedGrade B
    ResearchModerateCommunityStrongCalculator
  23. KLOW Blend packs BPC-157, TB-500, GHK-Cu, and KPV into one 80mg recovery vial. Community users report improved skin elasticity and gut comfort during GLP-1 therapy. No human trials exist for the combined formulation, but individual component data spans hundreds of preclinical studies.

    Healing & RecoveryResearch onlyGrade C
    ResearchNoneCommunityWeakCalculator
  24. 24SLU-PP-332

    SLU-PP-332 is a synthetic ERR agonist that mimics aerobic exercise at the gene level. Mouse data show 12% weight loss and 70% longer running times in 28 days. No human trials exist. Community protocols use 10 to 50 mg/day subcutaneous injection.

    MetabolicResearch onlyGrade CRising
    ResearchWeakCommunityWeakCalculator
  25. 25Tesamorelin

    Tesamorelin is the only FDA-approved GHRH analog for visceral fat reduction, backed by Phase 3 data in 816 patients. Originally indicated for HIV lipodystrophy, it's now widely used off-label for belly fat and GH optimization. The catch is that visceral fat returned within six months of stopping in the trials.

    Growth HormoneFDA approvedGrade A
    ResearchStrongCommunityStrongCalculator
  26. CJC-1295 (No DAC) triggers natural GH pulses with a half-life estimated at about 30 minutes. Paired with Ipamorelin in most protocols, it's the community's preferred GHRH analog for sleep, recovery, and body composition. No clinical trials of any kind exist for this specific form.

    Growth HormoneResearch onlyGrade B
    ResearchWeakCommunityStrongCalculator
  27. NA-Selank Amidate extends native Selank's anxiolytic and nootropic effects from minutes to hours through dual peptide stabilization. Approved in Russia under the parent formulation for GAD. No direct clinical trials exist for this specific modification. Research peptide only, not FDA approved.

    CognitiveResearch onlyGrade B
    ResearchWeakCommunityModerate
  28. 28NAD+

    NAD+ injectable protocols produce rapid cellular energy restoration and sirtuin activation. A 2019 IV infusion study confirmed 398% plasma elevation above baseline. Subcutaneous maintenance dosing at 100 to 250 mg twice weekly is the community standard for longevity use, though RCT evidence for wellness claims is still catching up.

    Anti-AgingResearch onlyGrade B
    ResearchModerateCommunityStrongCalculator
  29. 29BAM-15

    BAM-15 is a selective mitochondrial uncoupler that reduced fat mass and improved insulin sensitivity in mice without raising body temperature. Oral and non-stimulant, it draws interest as a safer DNP alternative, though zero human trials exist and community doses fall far below allometric estimates.

    MetabolicResearch onlyGrade C
    ResearchWeakCommunityWeak
  30. SS-31 (elamipretide) earned FDA accelerated approval for Barth syndrome in September 2025, targeting mitochondrial cardiolipin to restore energy production. Community users run 2 to 10 mg daily for fatigue and longevity. Injection site reactions affect nearly everyone at some point.

    Anti-AgingFDA approvedGrade A
    ResearchModerateCommunityWeakCalculator
How this list is made

Score = 40% Google search impressions on the peptide and calculator pages (28 days), 40% page views on the same pages (30 days), 20% actions on this site (calculator runs, saves, protocols started). Each input is log-scaled so one giant page cannot hide the rest. A peptide is listed only with at least 50 page views in 30 days and a score of 40 or more. Rising means its last seven days outran the site. Counts are totals, never people. This ranking was built on Oct 8, 2026.

Questions

No. Popularity measures attention. The safety grade, the FDA status and the research vs community meters on each card are the signals to read before anything else.

When the ranking is rebuilt from the latest 28 to 30 days of site activity and search data. This version was built on Oct 8, 2026.

It needs at least 50 page views in 30 days and a score of 40. Peptides with a calculator page but little search demand, or search demand but few visits, sit lower or drop off.